Arrow-right Camera
The Spokesman-Review Newspaper

The Spokesman-Review Newspaper The Spokesman-Review

Spokane, Washington  Est. May 19, 1883
Cloudy 29° Cloudy
News >  Health

How a missing gene led South African scientists to find omicron

UPDATED: Wed., Dec. 1, 2021

A health worker prepares a dose of the Pfizer-BioNTech Comirnaty branded COVID-19 vaccine at a mass vaccination site at Athlone Stadium in Cape Town, South Africa, on Aug. 20.  (Dwayne Senior/Bloomberg)
A health worker prepares a dose of the Pfizer-BioNTech Comirnaty branded COVID-19 vaccine at a mass vaccination site at Athlone Stadium in Cape Town, South Africa, on Aug. 20. (Dwayne Senior/Bloomberg)
By Antony Sguazzin Bloomberg

In early November, laboratories in South Africa’s Gauteng province began picking up something unusual while processing COVID-19 tests: They weren’t able to detect the virus gene that creates the spike protein enabling the pathogen to enter human cells and spread.

Around the same time, doctors in the region saw a sudden flood of patients with fatigue and headaches. The new cases appeared after weeks of calm that ensued following a delta variant-driven third coronavirus wave, which had ripped through Johannesburg and the capital Pretoria in July.

The developments heralded the onset of a wave of infections with the omicron variant in the country. It swiftly became the dominant strain and has driven a new surge in cases. The Nov. 25 announcement of its discovery triggered global panic and a market meltdown, with countries including the U.K. and the U.S. imposing flight bans to and from South Africa. By Tuesday, the mutation had been found in at least 15 countries.

The anomalies in samples were first detected by scientists at the privately owned Lancet Laboratories, who sounded the alarm, according to Glenda Gray, the president of the South African Medical Research Council. “They didn’t know what was wrong so they alerted the virologists, who began to sequence the samples,” she said in a Monday interview.

Junior Lancet scientist Alicia Vermeulen was credited with making the initial find on the afternoon of Nov. 4, when she noticed an anomaly in a single positive test and told her manager, according to News24, a South African news website. Over the next week, the same anomaly was picked up several times, and Allison Glass, head of molecular pathology at Lancet and a member of the government’s Ministerial Advisory Council on COVID-19, was informed, the website said.

Together with the National Institute for Communicable Diseases, Lancet was able to determine by Nov. 22 that there was a new variant, initially known as B.1.1.529, News24 reported. The S-gene couldn’t be detected because it had mutated, it said.

Scientists in Botswana had meanwhile also picked up the same anomalies in samples from tests conducted on travelers in early November, and the quirk also surfaced in a sample taken from a person who had returned to Hong Kong from South Africa and was in quarantine. The data was uploaded onto GISAID, a global repository, and quickly leaked. By Nov. 24, there were initial reports about the new variant in the British media.

Nicholas Crisp, acting director general of South Africa’s Department of Health, said he was first informed on the evening of Nov. 24. Other key government officials were told early the next day, and a news conference was hastily convened, where Tulio de Oliveira, the head of two gene-sequencing institutes in South Africa, announced the discovery.

For now, doctors say, omicron seems to be causing mild disease. But with the outbreak initially taking off in a relatively young cohort of college students, it’s difficult to tell what the effect may be once it takes hold in older, more vulnerable segments of the population. “Whatever I tell you today may be false tomorrow,” Gray said.

The World Health Organization has warned of the potential for COVID-19 surges with “severe consequences” fueled by omicron, whose constellation of mutations suggests it might be both more transmissible and capable of evading the immunity provided by vaccination or a prior infection.

The speed of the discovery is a testament to South Africa’s gene-sequencing capabilities that were built up with the aid of research money that was plowed into tackling other diseases. The country has the most people infected with HIV in the world and has one of the largest tuberculosis epidemics.

“South Africa has some world-class virologists and gene sequencers. We have this because of HIV and TB,” Gray said. “All of these people have transitioned to COVID-19.”

The events that unfolded following omicron’s discovery have dismayed the South African government and business groups. Flight bans were quickly imposed just as the country’s crucial summer holiday season began and threaten to derail efforts to rebuild an economy that contracted by the most in at least 27 years in 2020.

“We have to question the purpose of creating the panic that the public announcement has no doubt created,” said the South African Chamber of Commerce and Industry, the country’s biggest business group.

While the WHO said South Africa and Botswana should be thanked for the speed of the announcement, the response has instead felt like a punishment. “Our scientists did what they were supposed to do, they did what they are ethically obliged to do,” said Angelique Coetzee, the chairwoman of the South African Medical Association. “Now we are the villains of the global travel community.”

Bloomberg’s Frank Connelly contributed to this report.

The Spokesman-Review Newspaper

Local journalism is essential.

Give directly to The Spokesman-Review's Northwest Passages community forums series -- which helps to offset the costs of several reporter and editor positions at the newspaper -- by using the easy options below. Gifts processed in this system are not tax deductible, but are predominately used to help meet the local financial requirements needed to receive national matching-grant funds.

Active Person

Subscribe to the Coronavirus newsletter

Get the day’s latest Coronavirus news delivered to your inbox by subscribing to our newsletter.